标题
Phosphorylation of PBK/TOPK Tyr74 by JAK2 promotes Burkitt lymphoma tumor growth
作者
关键词
-
出版物
CANCER LETTERS
Volume 544, Issue -, Pages 215812
出版商
Elsevier BV
发表日期
2022-07-01
DOI
10.1016/j.canlet.2022.215812
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
- (2021) Armando N. Bastidas Torres et al. HAEMATOLOGICA
- Activation of NF-κB by TOPK upregulates Snail/Slug expression in TGF-β1 signaling to induce epithelial-mesenchymal transition and invasion of breast cancer cells
- (2020) Young-Ju Lee et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Burkitt Lymphoma — Subtypes, Pathogenesis, and Treatment Strategies
- (2020) Ariela Noy Clinical Lymphoma Myeloma & Leukemia
- Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis
- (2019) Ze‐Long Liu et al. Cancer Medicine
- Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis
- (2019) Amanda Mogul et al. ANNALS OF PHARMACOTHERAPY
- Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells
- (2019) Juanjuan Xiao et al. Cell Death & Disease
- P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling
- (2018) Le Wang et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Targeting PRPK Function Blocks Colon Cancer Metastasis
- (2018) Tatyana Zykova et al. MOLECULAR CANCER THERAPEUTICS
- B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma
- (2018) Li Li et al. BLOOD
- T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics
- (2018) Katharine J. Herbert et al. Cell Death & Disease
- ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
- (2017) Ge Gao et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the T-Lak cell originated protein kinase by OTS964 shrinks the size of power-law coded heterogeneous glioma stem cell populations
- (2017) Michiya Sugimori et al. Oncotarget
- A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models
- (2017) Nannan Zhang et al. Oncotarget
- microRNA-375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways
- (2017) Ran Wei et al. Oncotarget
- Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma
- (2016) Daniel Beck et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
- (2016) Vincent Ribrag et al. LANCET
- TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun
- (2016) Ying Li et al. Oncotarget
- Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon
- (2016) Juanjuan Xiao et al. Oncotarget
- Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase
- (2016) Xiaoyu Zeng et al. Oncotarget
- PDZ-binding kinase/T-LAK cell-originated protein kinase is a target of the fucoidan from brown alga Fucus evanescens in the prevention of EGF-induced neoplastic cell transformation and colon cancer growth
- (2016) Olesia S. Vishchuk et al. Oncotarget
- TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer
- (2015) Huimin Sun et al. Oncotarget
- TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis
- (2014) Y. Matsuo et al. Science Translational Medicine
- A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
- (2013) A. M. Evens et al. ANNALS OF ONCOLOGY
- Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
- (2013) L. J. Costa et al. BLOOD
- TOPK and PTEN participate in CHFR mediated mitotic checkpoint
- (2013) Swapnil R. Shinde et al. CELLULAR SIGNALLING
- PBK/TOPK Expression During TPA-Induced HL-60 Leukemic Cell Differentiation
- (2012) Yu-Hong Liu et al. Asian Pacific Journal of Cancer Prevention
- Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
- (2012) L. Zhang et al. BLOOD
- Novel TOPK Inhibitor HI-TOPK-032 Effectively Suppresses Colon Cancer Growth
- (2012) D. J. Kim et al. CANCER RESEARCH
- Burkitt's lymphoma
- (2012) Elizabeth M Molyneux et al. LANCET
- T-LAK Cell-originated Protein Kinase (TOPK) Phosphorylation of MKP1 Protein Prevents Solar Ultraviolet Light-induced Inflammation through Inhibition of the p38 Protein Signaling Pathway
- (2011) Shengqing Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- T-LAK Cell-originated Protein Kinase (TOPK) Phosphorylation of Prx1 at Ser-32 Prevents UVB-induced Apoptosis in RPMI7951 Melanoma Cells through the Regulation of Prx1 Peroxidase Activity
- (2010) Tatyana A. Zykova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Critical roles of T-LAK cell-originated protein kinase in cytokinesis
- (2009) Jae-Hyun Park et al. CANCER SCIENCE
- Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach
- (2009) Cristiana Bellan et al. HEMATOLOGICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started